Hepatic Effects of Estrogen on Plasma Distribution of Small Dense Low-Density Lipoprotein and Free Radical Production in Postmenopausal Women
- PMID: 26903399
- PMCID: PMC7399267
- DOI: 10.5551/jat.33175
Hepatic Effects of Estrogen on Plasma Distribution of Small Dense Low-Density Lipoprotein and Free Radical Production in Postmenopausal Women
Abstract
Aim: Hepatic effects of estrogen therapy on low-density lipoprotein (LDL) subfraction or oxidative stress have not been previously evaluated. The purpose of the present study was to investigate whether the differential hepatic effects of estrogen affect plasma distribution of small dense LDL and free radical production in postmenopausal women.
Methods: In all, 45 postmenopausal women were given 0.625 mg/day of oral conjugated equine estrogen (CEE) (n=15), 1.0 mg/day of oral 17β estradiol (E2) (n=15), or 50 μg/day of transdermal 17βE2 (n=15) for 3 months. Subjects received either estrogen alone or with dydrogesterone at 5 mg/day. Plasma concentrations of sex hormone-binding globulin (SHBG), lipids, metallic ions, and derivatives of reactive oxygen metabolites (d-ROMs) were measured.
Results: CEE, but not oral 17βE2, increased the plasma concentrations of triglyceride, copper (Cu), and d-ROMs and the ratio of small dense LDL/total LDL cholesterol, a marker for plasma distribution of small dense LDL. Transdermal 17βE2 decreased d-ROMs concentrations but did not significantly change other parameters. Plasma concentrations of SHBG increased in the 3 groups. Estrogen-induced changes in triglyceride correlated positively either with changes in SHBG (R=0.52, P=0.0002) or the ratio of small dense LDL/total LDL cholesterol (R=0.65, P<0.0001). Changes in Cu also correlated positively either with changes in SHBG (R=0.85, P<0.0001) or d-ROMs (R=0.86, P<0.0001).
Conclusion: The hepatic effects of different routes or types of estrogen therapy may be associated with plasma distribution of small dense LDL and free radical production in postmenopausal women.
Figures


Similar articles
-
Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women.Circulation. 2002 Oct 1;106(14):1771-6. doi: 10.1161/01.cir.0000032261.12632.d7. Circulation. 2002. PMID: 12356628
-
Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women.Circulation. 2003 Aug 19;108(7):808-13. doi: 10.1161/01.CIR.0000084552.54277.64. Epub 2003 Aug 4. Circulation. 2003. PMID: 12900341 Clinical Trial.
-
Effects of androgenic properties of progestin combined with ethinyl estradiol on vascular endothelial reactivity, plasma lipids and free radical production in women with endometriosis.J Obstet Gynaecol Res. 2021 Mar;47(3):941-948. doi: 10.1111/jog.14620. Epub 2021 Jan 6. J Obstet Gynaecol Res. 2021. PMID: 33410266
-
Estrogen-induced small low-density lipoprotein particles in postmenopausal women.Obstet Gynecol. 1998 Feb;91(2):234-40. doi: 10.1016/s0029-7844(97)00651-0. Obstet Gynecol. 1998. PMID: 9469282
-
[Investigation of atherosclerosis in postmenopausal women: alteration of atherosclerosis-associated factors and vascular atherosclerosis by oral and transdermal estrogen replacement].Rinsho Byori. 2013 Mar;61(3):256-62. Rinsho Byori. 2013. PMID: 23785796 Review. Japanese.
Cited by
-
Impact of Menopause and the Menstrual Cycle on Oxidative Stress in Japanese Women.J Clin Med. 2023 Jan 20;12(3):829. doi: 10.3390/jcm12030829. J Clin Med. 2023. PMID: 36769477 Free PMC article.
-
Protective Effects of Estrogen on Cardiovascular Disease Mediated by Oxidative Stress.Oxid Med Cell Longev. 2021 Jun 28;2021:5523516. doi: 10.1155/2021/5523516. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34257804 Free PMC article. Review.
-
The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis.Front Pharmacol. 2022 Apr 12;13:850815. doi: 10.3389/fphar.2022.850815. eCollection 2022. Front Pharmacol. 2022. PMID: 35496275 Free PMC article.
-
Biofunctional roles of estrogen in coronavirus disease 2019: Beyond a steroid hormone.Front Pharmacol. 2022 Oct 19;13:1003469. doi: 10.3389/fphar.2022.1003469. eCollection 2022. Front Pharmacol. 2022. PMID: 36339571 Free PMC article. Review.
-
Transgender Cardiovascular Health: Practical Management for the Clinician.Curr Atheroscler Rep. 2022 Sep;24(9):721-730. doi: 10.1007/s11883-022-01047-1. Epub 2022 Jun 29. Curr Atheroscler Rep. 2022. PMID: 35767118 Review.
References
-
- Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002; 288: 321-333 - PubMed
-
- Hodis HN: Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleve Clin J Med, 2008; 75: S3-S12 - PubMed
-
- Schnatz PF: Hormonal therapy: does it increase or decrease cardiovascular risk? Obstet Gynecol Surv, 2006; 61: 673-681 - PubMed
-
- Haines CJ, Farrell E: Menopause management: a cardiovascular risk-based approach. Climacteric, 2010; 13: 328-339 - PubMed
-
- Harman SM: Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. Gend Med, 2006; 3: 254-269 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous